III期黑色素瘤新辅助免疫治疗后病理反应与瘤床组织病理特征与生存相关
基于OpACIN-neo试验83例III期黑色素瘤患者淋巴结清扫标本,评估INMC病理评估原则的观察者间可重复性,并分析瘤床组织病理特征与无复发生存(RFS)的关系。结果显示病理反应评估重复性好(κ=0.879),高纤维化免疫治疗反应亚型与无复发及延长RFS相关,B淋巴细胞数量在高纤维化亚型中显著增加。
要点
- INMC标准评估病理反应观察者间重复性好(κ=0.879)。
- 高纤维化反应亚型与无复发(P=0.008)和延长RFS(P=0.019)相关。
- 病理无反应(pNR,>50%存活肿瘤)者中复发者均有≥70%存活黑色素瘤。
核心结论
- INMC标准评估病理反应重复性好,高纤维化免疫治疗反应亚型与改善RFS相关,可能为生物标志物。
研究设计与样本
- OpACIN-neo临床试验中83例III期黑色素瘤患者淋巴结清扫标本的病理特征评估,采用irPR评分和新型ITRS评分,29例进行流式细胞分析。
主要发现
- 病理反应评估观察者间重复性好(κ=0.879),残余存活黑色素瘤百分比组内相关系数=0.965。
- 高纤维化免疫治疗反应亚型与无复发(P=0.008)和延长RFS(P=0.019)最强相关。
- 整个队列中较高ITRS和irPR评分与无复发相关(P=0.002和P≤0.0001)。
- 高纤维化亚型患者B淋巴细胞数量显著增加(P=0.046)。
- 病理无反应(pNR,>50%存活肿瘤)患者中,复发者均有≥70%存活黑色素瘤。
关键数值与推荐
- INMC病理反应评估标准显示强观察者间重复性(κ=0.879)。
- 高纤维化反应亚型与无复发(P=0.008)和延长RFS(P=0.019)相关。
- pNR定义为>50%存活肿瘤,复发者均有≥70%存活黑色素瘤。
- 较高ITRS和irPR评分与无复发相关(P=0.002和P≤0.0001)。
临床怎么用
- 采用INMC标准评估新辅助免疫治疗后的病理反应具有良好重复性。
- 高纤维化反应亚型可辅助识别复发风险较低的患者。
- pNR患者中≥70%存活黑色素瘤可能提示更高复发风险,需验证。
局限性
- pNR阈值重新分类为≥70%存活黑色素瘤及纳入<10%纤维化亚型标准需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines for pathological evaluation of neoadjuvant specimens and pathological response categories have been developed by the International Neoadjuvant Melanoma Consortium (INMC). As part of the Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) clinical trial of neoadjuvant combination anti-programmed cell death protein 1/anti-cytotoxic T-lymphocyte-associated protein 4 immunotherapy for stage III melanoma, we sought to determine interobserver reproducibility of INMC histopathological assessment principles, identify specific tumour bed histopathological features of immunotherapeutic response that correlated with recurrence and relapse-free survival (RFS) and evaluate proposed INMC pathological response categories for predicting recurrence and RFS. PATIENTS AND METHODS: Clinicopathological characteristics of lymph node dissection specimens of 83 patients enrolled in the OpACIN-neo clinical trial were evaluated. Two methods of assessing histological features of immunotherapeutic response were evaluated: the previously described immune-related pathologic response (irPR) score and our novel immunotherapeutic response score (ITRS). For a subset of cases (n = 29), cellular composition of the tumour bed was analysed by flow cytometry. RESULTS: There was strong interobserver reproducibility in assessment of pathological response (κ = 0.879) and percentage residual viable melanoma (intraclass correlation coefficient = 0.965). The immunotherapeutic response subtype with high fibrosis had the strongest association with lack of recurrence (P = 0.008) and prolonged RFS (P = 0.019). Amongst patients with criteria for pathological non-response (pNR, >50% viable tumour), all who recurred had ≥70% viable melanoma. Higher ITRS and irPR scores correlated with lack of recurrence in the entire cohort (P = 0.002 and P ≤ 0.0001). The number of B lymphocytes was significantly increased in patients with a high fibrosis subtype of treatment response (P = 0.046). CONCLUSIONS: There is strong reproducibility for assessment of pathological response using INMC criteria. Immunotherapeutic response of fibrosis subtype correlated with improved RFS, and may represent a biomarker. Potential B-cell contribution to fibrosis development warrants further study. Reclassification of pNR to a threshold of ≥70% viable melanoma and incorporating additional criteria of <10% fibrosis subtype of response may identify those at highest risk of recurrence, but requires validation.
引用
- Rawson RV, Adhikari C, Bierman C, et al. Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Ann Oncol. 2021. PMID: 33744385. doi:10.1016/j.annonc.2021.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。